Updated Jul 16, 2026
Elsesser Adam has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $30.06M.
Adam Elsesser is the CEO and a Director of Penumbra Inc, a company specializing in medical devices for thrombectomy and embolization. Under his leadership, Penumbra has focused on developing innovative solutions for vascular diseases.
| Role | CEO, Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | PEN | Penumbra Inc | G — Bona-fide gift | 77.0K | $0.00 | |
| 2025-09-03 | PEN | Penumbra Inc | S — Open-market sale | 1.2K | $270.81 | $325K |
| 2025-09-03 | PEN | Penumbra Inc | S — Open-market sale | 7.6K | $270.09 | $2.05M |
| 2025-09-03 | PEN | Penumbra Inc | S — Open-market sale | 4.7K | $269.26 | $1.26M |
| 2025-09-03 | PEN | Penumbra Inc | S — Open-market sale | 2.4K | $268.41 | $631K |
| 2025-09-03 | PEN | Penumbra Inc | M — Option exercise | 28.0K | $30.00 | $839K |
| 2025-08-20 | PEN | Penumbra Inc | S — Open-market sale | 100 | $256.50 | $26K |
| 2025-08-20 | PEN | Penumbra Inc | S — Open-market sale | 6.2K | $254.99 | $1.59M |
| 2025-08-20 | PEN | Penumbra Inc | S — Open-market sale | 9.1K | $254.27 | $2.32M |
| 2025-08-20 | PEN | Penumbra Inc | S — Open-market sale | 459 | $252.86 | $116K |
| 2025-08-20 | PEN | Penumbra Inc | M — Option exercise | 28.0K | $30.00 | $839K |
| 2025-08-06 | PEN | Penumbra Inc | S — Open-market sale | 30 | $240.56 | $7K |
| 2025-08-06 | PEN | Penumbra Inc | S — Open-market sale | 1.8K | $239.52 | $434K |
| 2025-08-06 | PEN | Penumbra Inc | S — Open-market sale | 3.8K | $238.81 | $918K |
| 2025-08-06 | PEN | Penumbra Inc | S — Open-market sale | 7.9K | $238.04 | $1.87M |
| 2025-08-06 | PEN | Penumbra Inc | S — Open-market sale | 2.5K | $236.78 | $589K |
| 2025-08-06 | PEN | Penumbra Inc | M — Option exercise | 28.0K | $30.00 | $839K |
| 2025-07-23 | PEN | Penumbra Inc | S — Open-market sale | 3.9K | $233.86 | $912K |
| 2025-07-23 | PEN | Penumbra Inc | S — Open-market sale | 8.6K | $233.29 | $2.01M |
| 2025-07-23 | PEN | Penumbra Inc | S — Open-market sale | 3.6K | $232.11 | $842K |
Adam Elsesser is the CEO and a Director of Penumbra Inc, a company specializing in medical devices for thrombectomy and embolization. Under his leadership, Penumbra has focused on developing innovative solutions for vascular diseases.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 38 open-market sales ($30.06M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Elsesser Adam profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.